Journal
CLINICAL INFECTIOUS DISEASES
Volume 30, Issue -, Pages S151-S159Publisher
UNIV CHICAGO PRESS
DOI: 10.1086/313852
Keywords
-
Categories
Funding
- NIAID NIH HHS [R01AI33835, UO1AI38858, UO1AI41089] Funding Source: Medline
Ask authors/readers for more resources
Many factors are involved in the success or failure of antiretroviral therapy. Recent data suggest that there are significant differences in drug absorption and disposition for the protease inhibitor class of antiretroviral drugs, and relationships between plasma concentrations and their antiviral effect have been described. Consequently, the issue of whether therapeutic drug monitoring should be employed for patients receiving treatment with these drugs has arisen. Several criteria must be met before a drug is considered a candidate for therapeutic drug monitoring. These criteria include pharmacological, clinical, and analytic components. Although not all the necessary criteria have yet been met, some of these components have been defined, and additional data are being generated. However, prospectively designed clinical trials must be completed to determine if monitoring protease inhibitor plasma concentrations provides additional clinical benefit to the patient.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available